Real world use of biologic drug levels and anti-drug antibodies in patients with psoriasis – does therapeutic drug monitoring have a place in routine clinical practice?

References

• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.
   PubMed Web of Science ®Google Scholar
• Smith C, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 – a rapid update. Br J Dermatol. 2020;183(4):628–637.
   PubMed Web of Science ®Google Scholar
• Owczarczyk-Saczonek A, Owczarek W, Osmola-Mańkowska A, et al. Secondary failure of TNF-α inhibitors in clinical practice. Dermatol Ther. 2019;32(1):e12760.
   PubMed Web of Science ®Google Scholar
• Zorlu O, Bülbül Başkan E, Yazici S, et al. Predictors of drug survival of biologic therapies in psoriasis patients. J Dermatolog Treat. 2020;2020:1–6.
   Web of Science ®Google Scholar
• De Keyser E, Busard C, Lanssens S, et al. Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on ustekinumab. Ther Drug Monit. 2019;41(5):634–639.
   PubMed Web of Science ®Google Scholar
• Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–2130.
   PubMed Web of Science ®Google Scholar
• Chiu H, Chu T, Cheng Y, et al. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PLoS One. 2015;10(11):e0142930.
   PubMed Web of Science ®Google Scholar
• Menting S, Coussens E, Pouw M, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol. 2015;151(6):616–622.
   PubMed Web of Science ®Google Scholar
• Lønnberg A, Skov L. Co-morbidity in psoriasis: mechanisms and implications for treatment. Expert Rev Clin Immunol. 2017;13(1):27–34.
   PubMed Web of Science ®Google Scholar
• Jullien D, Prinz J, Nestle F. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol. 2015;135(1):31–38.
   PubMed Web of Science ®Google Scholar
• Lecluse L, Driessen R, Spuls P, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146(2):347.
   PubMedGoogle Scholar
• Hsu L, Snodgrass B, Armstrong A. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261–273.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Marini J, Song M, et al. Immunogenicity of guselkumab is not clinically relevant in patients with moderate-to-severe plaque psoriasis. J Invest Dermatol. 2019;139(8):1830–1834.e6.
   PubMed Web of Science ®Google Scholar
• Thomas L, Lee E, Wu J. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. J Dermatolog Treat. 2019;30(2):110–116.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong A, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
   PubMed Web of Science ®Google Scholar
• Kimball A, Kerbusch T, Aarle F, et al. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. Br J Dermatol. 2020;182(1):180–189.
   PubMed Web of Science ®Google Scholar
• Suleiman A, Minocha M, Khatri A, et al. Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019;58(10):1309–1321.
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316.
   PubMed Web of Science ®Google Scholar
• Murage M, Tongbram V, Feldman S, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483–1503.
   PubMed Web of Science ®Google Scholar
• Doshi J, Takeshita J, Pinto L, et al. Biologic adherence among psoriasis patients in the us medicare population. Value in Health. 2015;18(3):A186.
   Web of Science ®Google Scholar
• Warren R, Smith C, Yiu Z, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640.
   PubMed Web of Science ®Google Scholar
• Belinchon I, Rivera R, Blanch C, et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367.
   PubMed Web of Science ®Google Scholar
• Ovejero-Benito M, Muñoz-Aceituno E, Reolid A, et al. Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis. Am J Clin Dermatol. 2018;19(2):209–222.
   PubMed Web of Science ®Google Scholar
• Hansel K, Bianchi L, Lanza F, et al. Adalimumab dose tapering in psoriasis: predictive factors for maintenance of complete clearance. Acta Derm Venerol. 2017;97(3):346–350.
   PubMed Web of Science ®Google Scholar
• Singh S, Facciorusso A, Singh A, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123.
   PubMed Web of Science ®Google Scholar
• Dua P, Hawkins E, van der Graaf P. A Tutorial on Target-Mediated Drug Disposition (TMDD) models. CPT Pharmacometrics Syst Pharmacol. 2015;4(6):324–337.
   PubMedGoogle Scholar
• Timmermann S, Hall A. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis. Basic Clin Pharmacol Toxicol. 2019;125(1):16–25.
   PubMed Web of Science ®Google Scholar
• Suleiman A, Khatri A, Minocha M, et al. Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn’s Disease: analyses of phase I and II trials. Clin Pharmacokinet. 2019;58(3):375–387.
   PubMed Web of Science ®Google Scholar
• Jauslin P, Kulkarni P, Li H, et al. Population-pharmacokinetic modeling of tildrakizumab (MK-3222), an anti-interleukin-23-p19 monoclonal antibody, in healthy volunteers and subjects with psoriasis. Clin Pharmacokinet. 2019;58(8):1059–1068.
   PubMed Web of Science ®Google Scholar
• Bruin G, Loesche C, Nyirady J, et al. Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis. J Clin Pharmacol. 2017;57(7):876–885.
   PubMed Web of Science ®Google Scholar
• Excellence N. USTEKINUMAB | Drug | BNF content published by NICE [Internet]. Bnf.nice.org.uk. 2020; [cited 3 August 2020]. Available from: https://bnf.nice.org.uk/drug/ustekinumab.html#indicationsAndDoses.
   Google Scholar
• Excellence N. TILDRAKIZUMAB | Drug | BNF content published by NICE [Internet]. Bnf.nice.org.uk. 2020; [cited 3 August 2020]. Available from: https://bnf.nice.org.uk/drug/tildrakizumab.html#indicationsAndDoses.
   Google Scholar
• Ger T, Huang Y, Hui R, et al. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis. 2019;10:2040622319843756.
   Web of Science ®Google Scholar
• Smith C, Jabbar‐Lopez Z, Yiu Z, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–636.
   PubMed Web of Science ®Google Scholar
• Chimenti M, Spinelli F, Giunta A, et al. Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review. Drug Dev Res. 2014;75:S61–S63.
   PubMed Web of Science ®Google Scholar
• Feuerstein J, Nguyen G, Kupfer S, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–834.
   PubMed Web of Science ®Google Scholar
• Medina F, Plasencia C, Goupille P, et al. Current practice for therapeutic drug monitoring of biopharmaceuticals in rheumatoid arthritis. Ther Drug Monit. 2017;39(4):364–369.
   PubMed Web of Science ®Google Scholar
• Liau M, Oon H. Therapeutic drug monitoring of biologics in psoriasis. Biologics. 2019;13:127–132.
   PubMed Web of Science ®Google Scholar
• Egan C, Doherty G. Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment? Expert Opin Biol Ther. 2019;19(9):907–918.
   PubMed Web of Science ®Google Scholar
• Lillegraven S, Haavardsholm E. Subclinical treatment targets in rheumatology: lessons from randomized clinical trials in rheumatoid arthritis. Rheum Dis Clin North Am. 2019;45(4):593–604.
   PubMed Web of Science ®Google Scholar
• Carrascosa J, van Doorn M, Lahfa M, et al. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. J Eur Acad Dermatol Venereol. 2014;28(11):1424–1430.
   PubMed Web of Science ®Google Scholar
• Krieckaert C, Nair S, Nurmohamed M, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2015;74(2):361–368.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen O, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–927.
   PubMed Web of Science ®Google Scholar